Toxicity of weekly oral topotecan in relation to dosage for gynecologic malignancies: a phase I study.


The aim of this study was to determine the dose of weekly oral topotecan that allows safe administration and to evaluate the pharmacokinetics of this dose in patients with recurrent gynecologic malignancies. The first cohort of patients received oral topotecan 6 mg/week administered orally on days 1, 8, and 15 of a 28-day regimen. A standard 3+3 dose… (More)
DOI: 10.1097/CAD.0b013e32835396d4